Elsevier

Metabolism

Volume 62, Issue 4, April 2013, Pages 578-585
Metabolism

Clinical Science
High serum C1q-adiponectin/total adiponectin ratio correlates with coronary artery disease in Japanese type 2 diabetics

https://doi.org/10.1016/j.metabol.2012.10.011Get rights and content

Abstract

Objective

Adiponectin, an adipocyte-derived protein, has potential antiatherogenic properties. Low levels of serum total-adiponectin (Total-APN) correlate with diabetes and coronary artery disease (CAD). Adiponectin and C1q form a protein complex in blood, and serum C1q-binding adiponectin (C1q-APN) can be measured. We investigated the correlation between C1q-APN and CAD in patients with type 2 diabetes mellitus (T2DM).

Methods

The study subjects were 107 outpatients with T2DM who underwent evaluation for CAD. Blood C1q, Total-APN, high-molecular weight-adiponectin (HMW-APN) and C1q-APN were measured by enzyme-linked immunosorbent assays.

Results

Serum levels of C1q-APN/Total-APN ratio were higher in patients diagnosed with CAD (10.47 ± 0.59, mean ± SEM, n = 54) than those without CAD (8.88 ± 0.60, n = 53, p = 0.0482). Age- and sex-adjusted logistic regression analysis identified serum C1q-APN/Total-APN ratio and hypertension as significant and independent determinants of CAD. A high serum C1q-APN/Total-APN ratio was associated with 3.965-fold increase in CAD prevalence.

Conclusions

High serum C1q-APN/Total-APN ratio correlates with CAD in T2DM.

Introduction

Adiponectin is an adipocyte-derived plasma protein [1] present abundantly in injured arteries [2], [3] and atherosclerotic lesions [4]. It has anti-atherogenic and insulin-sensitizing properties [5]. Previous studies demonstrated a close relationship between low circulating levels of total-adiponectin (Total-APN, i.e., hypoadiponectinemia, < 4 μg/mL) and type 2 diabetes mellitus (T2DM) [6] and coronary artery disease (CAD) [7], [8], [9], [10]. Adiponectin circulates in blood mainly in three forms: trimer, hexamer, and high-molecular weight (HMW) form [11]. However, the main form of blood adiponectin remains to be elucidated. We recently reported that adiponectin forms a protein-complex with C1q in human blood, and introduced measurement of human serum C1q-binding adiponectin (C1q-APN), and serum C1q-APN/Total-APN ratio as a novel marker of the metabolic syndrome [12]. We also reported recently that serum C1q-APN/Total-APN ratio correlates with polyvascular lesions detected by vascular ultrasonography [13]. The activated complement system plays a role in atherosclerosis [14], [15], [16], [17]. These results suggest that adiponectin may have a protective role in activated complement system in the development of atherosclerosis. What proportion of tissue damage-defensive adiponectin forms protein complex with tissue damage-offensive C1q remains unclear. Analysis of this adiponectin complex, in addition to Total-APN, is likely to enhance our understanding of the pathogenesis of CAD.

The aim of the present study was to determine the role of serum C1q-APN in the pathogenesis of CAD in T2DM patients.

Section snippets

Participants

The study (ADMIT study; UMIN 000002271) subjects were 107 consecutive Japanese patients with T2DM, who visited the outpatient clinic of “Diabetes & Metabolic Station”, Osaka University Hospital, between September 2009 and September 2011. Patients treated with pioglitazone, which is known to increase serum levels of Total-APN and C1q-APN in T2DM [18], [19] and those with renal dysfunction [estimated glomerular filtration rate (eGFR) < 30 mL/min] [20] were excluded from the study. The Medical

Characteristics of T2DM patients

Table 1 summarizes the characteristics of the study subjects. C1q-APN correlated significantly and positively with Total-APN in all, males and females (Fig. 1A). There was no significant correlation between C1q-APN and C1q in all, males and females (Fig. 1B). C1q-APN correlated significantly and negatively with Total-APN in all and females, but not in males (Fig. 1C). C1q-APN/Total-APN correlated significantly and negatively with Total-APN in all, males and females (Fig. 1D). There were no

Discussion

The major finding of the present study was that high serum C1q-APN/Total-APN ratio, but not C1q-APN, correlates with CAD, in T2DM patients. High serum C1q-APN/Total-APN ratio was associated with 4-fold increase in CAD prevalence, independent of other CAD risk factors. Thus, high serum C1q-APN/Total-APN ratio (≥ 13.5) can be considered an important risk factor for CAD, in addition to low serum levels of Total-APN (< 4 μg/mL), hypoadiponectinemia, in T2DM.

A proposed relative cutoff value from the

Author contributions

AH and KK researched and analyzed the data. KK also participated in the concept and design of the study, interpretation of data and reviewed/edited the manuscript. HK analyzed the data. HN recruited the patients and collected the data. TF and IS contributed to the discussion and wrote the manuscript. All authors read and approved the final version of the manuscript.

Funding

This research was supported in part by a Grant-in-Aid for Scientific Research on Innovative Areas (Research in a proposed research area) "Molecular Basis and Disorders of Control of Appetite and Fat Accumulation" (#22126008, to T.F. and K.K.), and Osaka University's academia–industry collaboration policy position between Osaka University and Otsuka Pharmaceutical Co., Ltd.

Conflict of interests

KK, TF and IS are promotional speakers for Otsuka Pharmaceutical Co., Ltd. TF is a member of the “Department of Metabolism and Atherosclerosis”, a sponsored course endowed by Kowa Co. Ltd.. The company has a scientific officer who oversees the program. All other authors declare no competing interests. Human serum C1q-binding adiponectin complex assay is under patent application in Japan.

Acknowledgments

We thank all staff of the “Diabetes & Metabolic Station” for the excellent medical care, and Messrs Shigeo Takahashi, Suguru Akamatsu, and Tetsuya Oda for the statistical advice and helpful discussion, and Messrs Hideaki Tanaka and Tohru Hadama and Mrs. Miyuki Nakamura for the excellent technical assistance.

References (29)

  • Y. Okamoto et al.

    An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls

    Horm Metab Res

    (2000)
  • Y. Okamoto et al.

    Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice

    Circulation

    (2002)
  • K. Kishida et al.

    Molecular mechanisms of diabetes and atherosclerosis: role of adiponectin

    Endocr Metab Immune Disord Drug Targets

    (2012)
  • K. Hotta et al.

    Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients

    Arterioscler Thromb Vasc Biol

    (2000)
  • Cited by (14)

    • Chemerin levels as predictor of acute coronary events: A case-control study nested within the veterans affairs normative aging study

      2014, Metabolism: Clinical and Experimental
      Citation Excerpt :

      Adipose tissue, once thought to have a role primarily in energy storage, is now known to be a metabolically active endocrine organ, secreting hormones known as adipocytokines [39–41]. There is growing evidence that these adipocytokines may be a link between obesity and cardiovascular disease [42–46]. Chemerin has been recently identified as an adipocytokine with pro-inflammatory action that has been positively correlated with coronary atherosclerotic plaque burden and arterial stiffness in cross-sectional studies [32–34].

    • A protein profile of visceral adipose tissues linked to early pathogenesis of type 2 diabetes mellitus

      2014, Molecular and Cellular Proteomics
      Citation Excerpt :

      A higher serum FABP4 level was linked to obesity, insulin resistance, and T2DM (62, 63). The amount of the serum C1q-adiponectin complex showed a significant correlation with coronary artery disease in Japanese T2DM subjects (64). The amounts of S100A8/9 (calprotectin) in both urine and plasma were associated with chronic low-grade inflammation and insulin resistance (65, 66), and mRNA levels of S100A8 were elevated in the adipocyte fraction of obese mice (67).

    • Effect of adiponectin on cardiac β-catenin signaling pathway under angiotensin II infusion

      2014, Biochemical and Biophysical Research Communications
      Citation Excerpt :

      These results suggest that the effect of adiponectin on β-catenin signaling may be different in cell and tissue types and be dependent on stimulatory conditions affecting on β-catenin signaling. Our group recently showed that circulating adiponectin binds to complement C1q in human serum [19] and serum ratio of C1q-adiponectin complex/total adiponectin correlates with metabolic diseases [33]. The adiponectin treatment significantly ameliorated murine arthritis and inhibited the accumulation of complement C1q and C3 in the joints [18], suggesting that circulating adiponectin binds to and traps complement C1q in bloodstream and prevents the deposition of C1q in the joints.

    • The complement system in human cardiometabolic disease

      2014, Molecular Immunology
      Citation Excerpt :

      In addition to C3 and its downstream activation products, an array of other complement components has also been evaluated in relation to human CVD. The complex C1sC1rC1-INH is elevated in patients with CHD, while C1q was not different between T2DM patients with or without CHD (Hirata et al., 2013; Horvath et al., 2013). C4 and C4d do not appear to be altered in angina pectoris or in heart failure (Kosar et al., 1999; Yasuda et al., 1990), and C4 was associated with risk of stroke in a small but not in a large study (Cavusoglu et al., 2007; Engstrom et al., 2007b).

    View all citing articles on Scopus
    View full text